Sutimlimab Cad denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sutimlimab cad are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sutimlimab for Cold Agglutinin Disease — Duplicate Therapy

Sutimlimab is a complement C1s inhibitor approved by the FDA specifically for hemolytic anemia in adults with cold agglutinin disease (CAD). A "duplicate therapy" denial from BCBS typically means the plan has determined that sutimlimab overlaps with another agent the patient is already receiving, or that a previously authorized therapy is considered therapeutically equivalent. In practice, these denials often reflect a category-level comparison rather than a mechanism-specific analysis — and for CAD, that distinction matters significantly.

## Why This Denial Is Appealable

Sutimlimab has a distinct mechanism of action (selective proximal complement inhibition at C1s) that differs from the mechanisms of other agents sometimes used in hematologic conditions. A true duplicate-therapy determination requires evidence that the patient is already receiving an agent with equivalent efficacy for CAD via the same or a clinically comparable pathway. If the "duplicate" agent operates through a different mechanism or is being used for a different indication, the denial is not clinically supported. Consult sutimlimab's FDA-approved prescribing information and BCBS's own published hematology coverage policy to confirm whether a legitimate overlap exists.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the plan's deadline from the denial date. Request the specific clinical rationale and the identity of the "duplicate" agent BCBS identified.
• External review (ACA §2719): After a final adverse internal decision, request independent external review within approximately four months. An IRO with hematology expertise will evaluate whether a true therapeutic overlap exists.
• ERISA §503: Self-funded plan members may request the full administrative record and challenge the comparator-agent analysis.
• Expedited review: Available if clinical urgency (e.g., transfusion dependence, active hemolytic crisis) is documented.

## Documentation to Gather

• Confirmed CAD diagnosis with supporting laboratory documentation
• Current medication list with mechanisms of action and specific indications for each agent
• Treating hematologist's letter explaining why sutimlimab is not therapeutically duplicative and what clinical gap it addresses
• Response history to any prior or concurrent therapies, including inadequate responses or adverse effects
• FDA prescribing information for sutimlimab identifying its approved indication and mechanism
• BCBS's published hematology or rare disease coverage policy

## Criteria-Mapping Structure

Pull the exact duplicate-therapy language from BCBS's coverage policy. For each element of the duplicate-therapy definition, document the clinical facts that distinguish sutimlimab from the identified comparator. Address mechanism, indication, and clinical outcome separately. The treating hematologist's letter should explicitly state that no currently authorized agent addresses the same complement pathway for this patient's CAD presentation.